Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Tamanna Roshan Lal

Medical Biochemical Genetics Chevy Chase, MD Medical Doctor

NPI 1699069591 CMS profile 439840

5550 Friendship Blvd Ste 580, Chevy Chase, MD 20815

Open in the dashboard

General payments

$24,534

23 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$127,312 paid to institutions, not to them · program years 2019–2025

Through program year 2023, Tamanna Roshan Lal of Chevy Chase, MD is reported in the CMS Open Payments database as having received $24,534 across 23 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $127,312 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $3,320 1
2022 General $6,445 5
2021 General $5,400 4
2020 General $1,000 2
2019 General $8,369 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tamanna Roshan Lal
  • Maryland median
  • Middle half of Maryland
  • National median

In program year 2025, general payments to Tamanna Roshan Lal were reported at $0. Among 20,588 Maryland profiles paid that year, the median was $166 and the middle half received between $51 and $580.

Show as a table
Year Tamanna Roshan Lal Maryland median Middle half National median
2019 $8,369 $165 $50–$633 $163
2020 $1,000 $114 $37–$407 $114
2021 $5,400 $130 $36–$480 $132
2022 $6,445 $150 $45–$529 $149
2023 $3,320 $155 $47–$557 $160
2024 $0 $169 $53–$600 $164
2025 $0 $166 $51–$580 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. BioMarin Pharmaceutical Inc. $16,767 16 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $4,565 2 payments
  3. Shire North American Group Inc $3,200 4 payments
  4. Retrophin, Inc. $3 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $11,500 10 payments
  2. Consulting Fee $11,245 4 payments
  3. Travel and Lodging $1,518 4 payments
  4. Food and Beverage $268 4 payments
  5. Education $3 1 payment
Products named General payments · program years 2019–2023
  1. Palynziq $15,167 14 payments
  2. Kuvan $9,767 10 payments
  3. VPRIV $1,245 1 payment
  4. (820) Cholbam $3 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

23 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record